問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

陳彩雲

List

152Cases

2023-06-01 - 2025-12-31

Phase I/II

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients With and Without Mixed Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation

  • Condition/Disease

    Leukemia, Myeloid, Acute、 Leukemia, Lymphocytic, Acute

  • Test Drug

    DSP-5336

Participate Sites
3Sites

Recruiting3Sites

2020-10-20 - 2022-04-28

Phase III

A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

  • Condition/Disease

    Primary Immune Thrombocytopenia(ITP)

  • Test Drug

    Rozanolixizumab

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2019-09-15 - 2027-05-31

Phase I/II

A Phase I/IIa, Open-label, Multicenter Study of the Safety and Efficacy of CHO-H01 as a Single Agent to Subjects with Refractory or Relapsed Non-Hodgkin's Lymphoma

  • Condition/Disease

    Refractory or Relapsed Non-Hodgkin's Lymphoma

  • Test Drug

    CHO-H01

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2019-11-15 - 2026-01-31

Phase III

A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia.

  • Condition/Disease

    Chronic Lymphocytic Leukemia

  • Test Drug

    Acalabrutinib (ACP-196)

Participate Sites
4Sites

Recruiting4Sites

2021-07-26 - 2025-09-08

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2021-05-20 - 2023-05-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2021-04-01 - 2022-09-30

Phase III

An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

  • Condition/Disease

    Primary Immune Thrombocytopenia

  • Test Drug

    Rozanolixizumab

Participate Sites
8Sites

Not yet recruiting8Sites

2023-10-20 - 2026-12-31

Phase I

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

  • Condition/Disease

    B-cell Non Hodgkin Lymphoma、 Diffuse Large B Cell Lymphoma 、High-grade B-cell Lymphoma、 Follicular Lymphoma

  • Test Drug

    AZD0486

Participate Sites
4Sites

Recruiting4Sites

2021-04-01 - 2029-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2019-09-01 - 2022-12-31

Phase II

A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study)

  • Condition/Disease

    Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies

  • Test Drug

    ME-401

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

1 12 13 14 15 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB